[Comment on the STAR study: Comparison of the efficacy and tolerance of solifenacin and tolterodine retard in the treatment of overactive bladder]

Urologe A. 2006 Jul;45(7):847-51. doi: 10.1007/s00120-006-1121-8.
[Article in German]
No abstract available

MeSH terms

  • Analysis of Variance
  • Benzhydryl Compounds / administration & dosage*
  • Benzhydryl Compounds / adverse effects
  • Controlled Clinical Trials as Topic*
  • Cresols / administration & dosage*
  • Cresols / adverse effects
  • Double-Blind Method
  • Drug Tolerance
  • Female
  • Humans
  • Male
  • Middle Aged
  • Muscarinic Antagonists / administration & dosage
  • Muscarinic Antagonists / therapeutic use*
  • Phenylpropanolamine / administration & dosage*
  • Phenylpropanolamine / adverse effects
  • Prospective Studies
  • Quinuclidines / administration & dosage*
  • Quinuclidines / adverse effects
  • Solifenacin Succinate
  • Tetrahydroisoquinolines / administration & dosage*
  • Tetrahydroisoquinolines / adverse effects
  • Tolterodine Tartrate
  • Treatment Outcome
  • Urinary Bladder, Overactive / complications
  • Urinary Bladder, Overactive / drug therapy*
  • Urinary Incontinence / complications
  • Urinary Incontinence / drug therapy*

Substances

  • Benzhydryl Compounds
  • Cresols
  • Muscarinic Antagonists
  • Quinuclidines
  • Tetrahydroisoquinolines
  • Phenylpropanolamine
  • Tolterodine Tartrate
  • Solifenacin Succinate